Clinical trials: Advanced Solid Tumors (Phase 1)
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.
This study is being done to learn more about a new drug called Bapotulimab given in combination with Pembrolizumab. The purpose of this study is to learn if this new combination of drugs is safe for the participants, how it…
- Trial name
- NCT03666273
- Testing
- Bapotulimab (BAY1905254), Bapotulimab (BAY1905254) + Pembrolizumab (KEYTRUDA®)
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- Bayer
Metastatic Cancer, Solid Tumor
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors
- Conditions
- Metastatic Cancer, Solid Tumor, Pancreatic Cancer, Urothelial Carcinoma
- Trial name
- NCT04666688
- Testing
- LYT-200, Tislelizumab, Gemcitabine/nab-paclitaxel
- Where
- 12 sites in United States
- Volunteers
- 44 people
- Sponsor
- PureTech
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with binimetinib in treating patients with solid tumors that carry RAS alterations and that have spread to other places in the body…
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Triple-Negative Breast Carcinoma
- Trial name
- NCT05111561
- Testing
- BET Bromodomain Inhibitor ZEN-3694, Binimetinib, Biopsy Procedure
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific
Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy such as docetaxel work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00084786
- Testing
- docetaxel, gefitinib
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Solid Tumors, Adult
A Study of GC203 TIL in Advanced Solid Tumors (NF)
This study is a prospective, open-label, single-arm clinical trial aimed at evaluating the safety and efficacy of GC203 TIL therapy in treating malignant solid tumors that have failed standard treatment.
- Trial name
- NCT07256756
- Testing
- GC203 TIL
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Shanghai Juncell Therapeutics
Advanced Solid Tumor
A Clinical Study of SPH6516 Tablets in the Treatment of Advanced Solid Tumors.
To evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SPH6516 tablets in the treatment of advanced solid tumors.
- Trial name
- NCT06266923
- Testing
- SPH6516 tablets
- Where
- 2 sites in China
- Volunteers
- 16 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Advanced Solid Tumors
Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors
The primary purpose of this study is to assess the effect of multiple-dose administration of fluconazole on the single-dose intravenous (IV) pharmacokinetics (PK) of MLN4924; and to assess the effect of multiple-dose…
- Trial name
- NCT02122770
- Testing
- MLN4924, Fluconazole, Itraconazole
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Advanced Solid Tumor
A Phase I Study of QL1604 for Advanced Solid Tumors
In this study, patients with advance solid tumors will be treated with QL1604 monotherapy.
- Trial name
- NCT05801094
- Testing
- QL1604
- Where
- 2 sites in China
- Volunteers
- 71 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Advanced Solid Tumor Cancer
A Study to Evaluate Safety, PK and Efficacy of GH55 in Combination With GH21 in Patients With Solid Tumors
GH55 Capsule is a novel, highly selective small molecule dual mechanism ERK1/2 inhibitor. GH21 Capsule is a potent, orally active human SHP2 allosteric inhibitor.
- Trial name
- NCT07446725
- Testing
- Phase I dose escalation, Phase I: Dose Expansion, phase II
- Where
- China
- Volunteers
- 152 people
- Sponsor
- Suzhou Genhouse Bio Co., Ltd.
ADVANCED SOLID TUMORS
Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors
This is a phase I, multicenter, open-label, dose escalating clinical and pharmacokinetic study of PM01183 for patients with advanced solid tumors
- Trial name
- NCT00877474
- Testing
- PM01183
- Where
- 2 sites in United States, Spain
- Volunteers
- 30 people
- Sponsor
- PharmaMar
Advanced Solid Tumors
A Dose Escalation of Gimatecan Administered Orally to Japanese Patients With Advanced Solid Tumor.
This study assesses the tolerability, safety, efficacy and pharmacokinetics of gimatecan in Japanese patients. Gimatecan is administered orally for five consecutive days, every 28 days, to adult patients with advanced solid…
- Trial name
- NCT00410358
- Testing
- Gimatecan
- Where
- Japan
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumor
Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+
Open label, non-randomized, dose escalation and expansion Phase Ia/b trial to evaluate the safety and tolerability of the combination of neratinib plus paclitaxel, trastuzumab and pertuzumab to determine the recommended Phase…
- Trial name
- NCT02593708
- Testing
- Neratinib, Paclitaxel, Pertuzumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Michelle Melisko
Advanced Solid Tumors, Colorectal Cancer
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-151 at varying dose levels and frequencies, and subsequently in combination with irinotecan.
- Conditions
- Advanced Solid Tumors, Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT01520389
- Testing
- MM-151, MM-151 + irinotecan
- Where
- 4 sites in United States
- Volunteers
- 112 people
- Sponsor
- Merrimack Pharmaceuticals
Advanced Solid Tumors
A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors
The reason for the study is to find out if MEDI5395 and durvalumab will work and be safe for the treatment of solid tumors.
- Trial name
- NCT03889275
- Testing
- MEDI5395, Durvalumab
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 39 people
- Sponsor
- MedImmune LLC
Solid Tumor, Malignant Lymphoma
Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma
This is an open-label, Phase 1, dose escalation study of oral ARQ 092 administered to subjects with advanced solid tumors and recurrent malignant lymphoma.
- Conditions
- Solid Tumor, Malignant Lymphoma, Tumor
- Trial name
- NCT01473095
- Testing
- ARQ 092
- Where
- 7 sites in United States
- Volunteers
- 120 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Advanced Solid Tumor, Non-small Cell Lung Cancer
IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors
This is a multi-center, open-label, dose-escalation and cohort-expansion phase I clinical study to evaluate the safety and tolerability, pharmacokinetics profile, efficacy and immunogenicity of IMM2520 in subjects with advanced…
- Conditions
- Advanced Solid Tumor, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Breast Cancer
- Trial name
- NCT05780307
- Testing
- IMM2520
- Where
- China
- Volunteers
- 48 people
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Unspecified Adult Solid Tumor, Protocol Specific
Vaccine Therapy in Treating Patients With Advanced Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have advanced cancer.
- Trial name
- NCT00004881
- Testing
- MVA-MUC1-IL2 vaccine
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
This study is one single group of participants with non-small cell lung cancer (NSCLC) who have not been cured by other treatments. It is the first time the drug has been used in humans. There will be two parts and a sub-study.
- Conditions
- Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT03401385
- Testing
- Datopotamab Deruxtecan (Dato-DXd), Steroid Containing Mouthwash, Non-Steroid Containing Mouthwash
- Where
- 18 sites in United States, Japan
- Volunteers
- 890 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Solid Tumor, Adult
Advanced or Recurrent Solid Tumors Treated With SHetA2
The purpose of this research is to test the safety of the study drug (OK-1) and see what effects (good and bad) this drug has on patients with recurrent solid tumors.
- Trial name
- Okgyn1 (NCT04928508)
- Testing
- OK-1
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Oklahoma
Solid Tumors, Advanced Cancer
AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin
The goal of this clinical research study is to find the highest safe dose of AMG 531 that will decrease the risk and severity of thrombocytopenia (low platelet counts) in patients who have received chemotherapy.
- Trial name
- NCT00147225
- Testing
- AMG 531, Carboplatin, Adriamycin
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.